

Cynata Receives \$1.7m R&D TI Refund and Repays R&D TI Loan

Melbourne, Australia; 7 October 2026: [Cynata Therapeutics Limited](#) (ASX: “CYP”, “Cynata”, or the “Company”), advises that its \$1,694,183 Research and Development Tax Incentive (R&D TI) Refund for the 2025/2026 financial year has been received.

The R&D TI is an important Australian Government program that encourages companies to engage in research and development benefiting Australia by providing a tax offset for eligible activities such as the development of Cynata’s unique and proprietary Cymerus™ therapeutic mesenchymal stromal cell (MSC) products.

The refund has been used to repay the Company’s R&D TI loan (see announcements dated [6 July 2026](#) and [30 September 2026](#)). The loan is now fully repaid, and the Company has no further obligations to the lender. After repayment of the loan, the net proceeds from the R&D TI refund are \$1,066,884.

ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited’s (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Pty Ltd](#).